The cost of Amphotericin B is expected to plunge globally by the end of March, driven by several major influences. This downward trend is fueled by lower shipping costs, reduced demand from downstream sectors, and enough market supply. Moreover, market participants are likely to reduce Amphotericin B prices—therefore March—the end of the quarter—to clear out old stock and stabilize market conditions.

With the reopening of manufacturing following the February vacation, China has greatly shaped the worldwide market as a large producer of APIs including Amphotericin B. Chinese manufacturing resumption sharply raised supply, therefore enhancing Amphotericin B availability worldwide. As production levels and export shipments stabilized, consumer pressures relaxed, which should push Amphotericin B prices lower.

Market prices of Amphotericin B decreased in the Western sector in March because supply chain conditions improved as demand became weaker. Ocean shipping capacity made an almost complete rebound after Lunar New Year and multiple key origin points have enough equipment available for shipment. The rise in shipping capacity caused rates for transpacific containers to decrease which lowered the expenses for delivering Amphotericin B from China to Western markets. Additionally, with factories in Asia back to full production levels, the supply of Amphotericin B has increased, easing market pressures. Meanwhile, stagnant demand in March has further weakened price support, creating a scenario where higher supply and lower costs are likely to push Amphotericin B prices downward.

Destatis's February 2025 inflation rate of 2.8%, which was higher than the consensus, has put pressure on European consumers' ability to spend, hence reducing their purchasing power. The cautious consumerism behavior has, thus, resulted in decline in demand from the pharmaceutical and healthcare downstream sectors. Less procurement of products, including Amphotericin B, resulted in stockpiles of pharmaceutical products. The accumulation of inventory along with low market demand is expected to result in a decline in prices of Amphotericin B in the European market by this March.

The move by US President Donald Trump to double the tariffs on Chinese imports to 20% on March 4 is anticipated to reduce purchases from the US buyers. The increased uncertainty stemming from ongoing trade war and further tariffs will probably deter buying action as firms are confronted with price increases in importing products like Amphotericin B from China. This could cause US buyers to pull back or cancel orders leading to Amphotericin B prices falling in the US market.

Overall, the global market is likely to stay unpredictable, with shifting supply-demand fluctuations and ongoing trade disputes amid to cast an impact on Amphotericin B pricing in the subsequent months.